
ARCUS OVERVIEW

NYSE: RCUS



Global, clinical-stage biopharmaceutical company at the forefront of designing novel combination therapies for cancer



HIGHLY PRODUCTIVE DRUG DISCOVERY

Small Molecules & Antibodies Designed to Be Combined



Targets: CD73, HIF-2a, A2a/2b, AXL



Targets: TIGIT, PD-1, CD39

new molecules advancing into clinic each year




Accelerated

P 1/2 signalseeking & platform studies


DIVERSE PIPELINE & KEY DATA FOR 2025+

Different molecules in clinic

St Pivotal Readout



Cas Events



- · Cas + cabo efficacy data
- Additional data in early-line settings

PFS data

\$10B+



Addressable market opportunity in the U.S. based on expected drug treatable patient population

TOP-TIER PARTNERS FOR STRATEGIC & CLINICAL COLLABORATIONS



Funding:

~\$1.7B

- Holds ~30% equity stake in Arcus
- 50/50 Cost-sharing for certain optioned programs
- Co-development / co-commercialization in the U.S.

TAIHO PHARMA



STRONG FINANCIAL POSITION & CASH RUNWAY WITH **FUNDING THROUGH MULTIPLE PHASE 3 READOUTS**



927M cash, cash equivalents &

marketable securities as of 6/30/2025

HQ & RESEARCH CAMPUSES IN BAY AREA





Except as stated otherwise, this summary is provided as of 8/6/2025. For a more complete description of our business and risks and uncertainties that may affect forward-looking statements made in this summary, including the statement regarding funding through multiple Phase 3 readouts, please refer to our full corporate presentation and latest Form 10-K and Form 10-Q, which can be found at investors arcusbio.com. The runway estimate is based on cash, cash equivalents, marketable securities, and available facilities.

cabo: cabozantinib, cas: casdatifan, dom: domvanalimab, PFS: progression-free survival